$4.53
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

Treace Medical Concepts, Inc. engages in the design, manufacture, and marketing of orthopedic medical devices and biologic solutions. The company is headquartered in Ponte Vedra, Florida and currently employs 450 full-time employees. The company went IPO on 2021-04-23. The company is advancing the standard of care for the surgical management of bunion and related midfoot deformities. The company has patented the Lapiplasty 3D Bunion Correction System a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. The company has Adductoplasty Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities, the SpeedMTP Rapid Compression Implant for addressing bunions through big toe joint fusions, and two systems for minimally invasive osteotomy surgeries: the Nanoplasty 3D Minimally Invasive Bunion Correction System and the Percuplasty Percutaneous 3D Bunion Correction System. The company sells its products to physicians, surgeons, ambulatory surgery centers, hospitals, and stocking distributors.
Country

US

CEO

Mr. John Treace

IPO date

2021

Employees

450

ISIN

US89455T1097

Key stats

Open

$4.20

Volume

271.01K

Market cap

$290.05M

Prev. close

$4.46

Impl / hst vl

-

Open interest

$0.00

$4.20

Day’s Range

$4.53

$1.17

52W Range

$5.20

Valuation

16
Valuation score
Strongly Overvalued
P/E
-
P/S
1.41
P/B
3.80
Current ratio
-
Debt / Equity
0.72
ROE
-
Gross margin
-
Income growth
-11.63%
FCF growth
-265.13

Analysts estimates

Consensus rating
Hold

The average rating from top 5 analysts indicates that stock may significantly underperform the market

Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$4.76
The top 5 analysts forecasts that 12-month price may increase by 5.08%, with a low of $3.03 and a high of $7.35
$3.03
Low
$4.76
Avg
$7.35
High
Current price

Earnings

Q2 ‘26 revenue
$45.38M
Q2 ‘26 net income
-$15.87M
Revenue
Net income
Previous EPS
-$0.28
Estimate EPS
-$0.30
Actual EPS
Estimate EPS
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply